logo
episode-header-image
Sep 2023
26m 31s

Sep 08 2023 This Week in Cardiology

MEDSCAPE
About this episode

ESC Recap Part 2: ECLS-SHOCK, FIRE, MULTISTARS-AMI, HEART FID, and DANPACE II are the trials John Mandrola, MD, discusses in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:  https://www.medscape.com/twic

I. Cardiogenic Shock

ECMO for Shock in Acute MI Won't Help, May Harm: ECLS-SHOCK  https://www.medscape.com/viewarticle/995882

-   ECLS-SHOCK trial  https://www.nejm.org/doi/full/10.1056/NEJMoa2307227

-   ECMO-CS trial  https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062949

II. FIRE TRIAL

FIRE a Win for Physiology-Guided MI Complete Revascularization in Older Patients  https://www.medscape.com/viewarticle/995875

-   FIRE Trial  https://www.nejm.org/doi/full/10.1056/NEJMoa2300468

-   COMPLETE Trial  https://www.nejm.org/doi/full/10.1056/NEJMoa1907775

III. Immediate vs Staged Revascularization

Parity for Prompt vs Staged STEMI Complete Revascularization: MULTISTARS-AMI  https://www.medscape.com/viewarticle/995961

-   MULTISTARS AMI trial  https://www.nejm.org/doi/full/10.1056/NEJMoa2307823

-   Complete Revascularization Now Compulsory? MULTISTARS-AMI and FIRE in Context  https://www.medscape.com/viewarticle/995676

IV. Iron-Supplementation in Heart Failure

IV Iron Shows Only Modest Benefit in HF: HEART-FID  https://www.medscape.com/viewarticle/995874

-   HEART-FID   https://www.nejm.org/doi/full/10.1056/NEJMoa2304968

-   EHJ meta-analysis of Iron Supplementation   https://doi.org/10.1093/eurheartj/ehad586

V. AF Prevention with Pacing

Minimizing Atrial Pacing No Benefit in Sinus Node Disease: DANPACE II  https://www.medscape.com/viewarticle/996076

-   DANPACE II  https://doi.org/10.1093/eurheartj/ehad564

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine.  https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.  https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Up next
Jun 27
Jun 27 2025 This Week in Cardiology
FDA approves triple-drug polypill, a change of opinion, a deep dive into invasive pulmonary embolism therapies, heart disease trends, and diabetes care is on fire are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professio ... Show More
28m 58s
Jun 20
Jun 20 2025 This Week in Cardiology
A big, deep dive into CTA and fractional flow reserve CT, and a sobering report on the new EVOQUE valve are discussed by John Mandrola, MD, in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https ... Show More
32m 47s
Jun 13
Jun 13 2025 This Week in Cardiology
Listener feedback on cardiac sarcoidosis, SA node ablation, surgical AF ablation, chronic kidney disease protection, and recruiting for clinical trials are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. ... Show More
27m 15s
Recommended Episodes
Feb 2025
LifeBTK Trial: Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease
In this episode of Audible Bleeding, Jamila, Anh, and Naveed discuss the LifeBTK Trial with Principal Investigator Dr. Brian DeRubertis, where we discuss the new Abbott Esprit everolimus-eluting resorbable scaffold for the below-knee popliteal space. Guest: Dr. DeRubertis, is the ... Show More
47m 12s
Dec 2024
Top Takeaways from 2024: Interventional Cardiology with Deepak L. Bhatt, MD, MPH, MBA, FACC
In this interview, Deepak L Bhatt, MD, MPH, MBA, FACC, and Alison L. Bailey, MD FACC, discuss the Top Interventional Takeaways from 2024. Dr. Bhatt discusses the CLEAR SYNERGY, DanGer Shock, EARLY TAVR trials and more.   Jolly SS, d’Entremont MA, Lee SF, et al., for the CLEAR Inv ... Show More
16m 1s
Mar 2025
Episode 946: Time to Defibrillation
Contributor: Aaron Lessen, MD Educational Pearls: Quick background info Cardiac arrest is when the heart stops pumping blood for any reason. This is different from a heart attack in which the heart is still working but the muscle itself is starting to die. One cause of cardiac ar ... Show More
2m 30s
Oct 2020
64. Case Report: RV Infarction Treated with RVAD Support – Houston Methodist
CardioNerds (Amit Goyal & Daniel Ambinder) join Houston Methodist cardiology fellows (Isaac Tea, Stephanie Fuentes, Peter Rothstein) for a trip to Hermann Park! They discuss a challenging case of right ventricular (RV) infarction leading to acute RV failure treated with right ven ... Show More
1h 16m
Dec 2024
Episode 936: Etomidate vs. Ketamine for Rapid Sequence Intubation
Contributor: Ricky Dhaliwal MD Educational Pearls:  Etomidate was previously the drug of choice for rapid sequence intubation (RSI) However, it carries a risk of adrenal insufficiency as an adverse effect through inhibition of mitochondrial 11-β-hydroxylase activity A recent meta ... Show More
4m 58s
Apr 2024
Episode 899: Thrombolytic Contraindications
Contributor: Travis Barlock MD Educational Pearls: Thrombolytic therapy (tPA or TNK) is often used in the ED for strokes Use of anticoagulants with INR > 1.7 or  PT >15 Warfarin will reliably increase the INR Current use of Direct thrombin inhibitor or Factor Xa inhibitor  aPTT/P ... Show More
3m 51s
Nov 2023
Trial highlights from EACTS Annual Meeting 2023
Join our hosts Can Gollmann-Tepeköylü and Miia L Lehtinen for their late-breaking trials highlights presented at the 37th EACTS Annual Meeting in Vienna, including:  (2:40 - 8:53) Subannular Repair for Secondary Mitral Regurgitation with restricted systolic leaflet Motion (type I ... Show More
33m 36s
Jun 17
Clopidogrel Versus Aspirin For Long-term Maintenance Monotherapy In Patients With High Ischemic Risk After PCI
The SMART-CHOICE 3 trial demonstrated that clopidogrel monotherapy is more effective than aspirin monotherapy in reducing the risk of major adverse cardiac and cerebrovascular events in high-risk patients who completed standard dual antiplatelet therapy (DAPT) following percutane ... Show More
9m 15s